PFCS
RLMD icon

Pale Fire Capital SE’s Relmada Therapeutics RLMD Stock Holding History

Pale Fire Capital SE’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$220K Sell
31,650
-12,900
-29% -$61K 0.02% 51
2025
Q4 		$215K Buy
+44,550
New +$149K 0.01% 48

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Pale Fire Capital SE's RLMD Position: Q1 2026 in Review

Pale Fire Capital SE reduced its Relmada Therapeutics (RLMD) stake by 29% in Q1 2026, selling an estimated $61K and leaving 31,650 shares worth $220K. The position accounts for 0.02% of the portfolio, ranked #51.

Pale Fire Capital SE first reported a position in RLMD in Q4 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Pale Fire Capital SE held 31,650 shares of Relmada Therapeutics worth $220K as of Q1 2026.
  • Pale Fire Capital SE sold 12,900 Relmada Therapeutics shares in Q1 2026, an estimated $61K.
  • Relmada Therapeutics made up 0.02% of Pale Fire Capital SE's portfolio in Q1 2026, its #51 holding.
  • Pale Fire Capital SE first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Pale Fire Capital SE's 13F filing for Q1 2026, filed 14 May 2026.